查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1715464

口服蛋白质和胜肽市场按产品类型、配方、开发阶段、应用和最终用户划分—2025-2030 年全球预测

Oral Proteins & Peptides Market by Product Type, Formulation, Development Stage, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023 年口服蛋白质和胜肽市场价值为 61 亿美元，预计 2024 年将达到 68.9 亿美元，预计到 2030 年将以 13.27% 的复合年增长率增长，达到 146 亿美元。

主要市场统计数据
基准年2023年 61亿美元
预计年份：2024年 68.9亿美元
预测年份 2030 146亿美元
复合年增长率（%） 13.27%

口服蛋白质和胜肽已成为不断发展的治疗领域的焦点，为疾病管理和患者依从性提供了变革性的好处。近年来，生物技术和製剂科学的重大进步为这些分子超越传统管理障碍铺平了道路。人们越来越重视开发强大的口服给药系统，不仅可以确保生物有效性，还可以提高患者的舒适度和依从性。随着研究的深入和技术的发展，市场正在吸引製药开发商、医疗保健提供者和投资者的注意。

这份全面的评论详细介绍了当前的市场状况，并提供了对其未来成长轨蹟的见解。确定关键趋势，探索创新制定策略，并评估法规结构对市场成长的影响。此项分析是在技术快速进步和全球追求更有效、以患者为中心的护理的环境下组装的。本文针对的是那些致力于以证据为基础的决策和策略性市场介入的相关人员。随着患者需求的不断变化，口服蛋白质和胜肽市场将迎来颠覆性突破，重新定义治疗模式并优化治疗结果。

从策略角度来看，这本书是一个宝贵的知识中心，提供数据支援的见解和深入的定性分析，有助于阐明市场趋势。提供的见解重点在于临床进步和市场策略的整合，以解决未满足的医疗需求。最终，这些见解的综合凸显了在高度互联的市场中协调研究、创新和商业化活动的重要性，为转型之旅奠定了基础。

不断变化的市场条件及其策略影响

过去几年，在科学快速突破和全球医疗保健重点重新调整的推动下，口服蛋白质和胜肽市场发生了变革性的变化。药物输送系统的最新创新透过引入有效结合便利性和有效性的有前景的替代方案，挑战了长期以来对肠外给药的依赖。这一演变的基础是重新关注以患者为中心的方法、先进的生物技术以及研究机构和製药公司之间的战略伙伴关係。

新型封装技术的出现、胜肽稳定性的提高以及增强口服吸收的改进是这项转变的核心要素。监管机构也不断调整其框架以适应突破性疗法，从而加快核准并创造更有利于创新的环境。随着这些技术进步，市场相关人员已经开始转变策略，转向开发既能满足临床需求又能实现经济永续性的综合解决方案。决策者现在正在使用预测分析、巨量资料和基于风险的监控来简化开发平臺，同时最大限度地缩短产品上市时间。

此外，市场在全球投资流向方面正在经历重大调整，更加註重瞄准新兴治疗领域和服务不足的患者群体。因此，传统市场相关人员被迫重新思考其商业框架，并追求动态且灵活的经营模式。这种转变不仅仅是一种渐进的改进，而是一种范式转变，它将重新定义竞争策略并塑造新的临床价值提案。在这种环境下，采取积极主动的方法，并以扎实的研究和无缝的执行为后盾，对于获得这些转型变革的好处至关重要。

影响产品开发和市场策略的关键细分洞察

对市场区隔的细緻了解有助于制定口服蛋白质和胜肽领域的策略规划和产品开发。我们从多个维度对市场进行了严格分析，每个维度都为我们提供有关市场结构和成长潜力的关键见解。首先，根据产品类型，我们区分基于胰岛素的蛋白质和胜肽疗法。此外，在此类别中，已确定了组合胰岛素、长效胰岛素类似物、速效胰岛素类似物和重组人类胰岛素等子区隔，以及与抑钙素为基础的疗法、Glucagon-Like Peptide-1受体促效剂和加压素类似物相对应的部分。这种详细的细分有助于深入了解治疗效果、市场渗透和创新趋势。

市场还根据配方进行细分，提供胶囊、液体、粉末和锭剂等各种选择，突显了给药形式的重要性。这些剂型经过不断测试和优化，以提高患者的依从性和临床结果。同时，开发阶段细分提供了对治疗成熟度的洞察，并分为 I 期和 II 期临床试验、III 期临床试验、开发后监测和临床前试验。这种细分不仅突显了研究强度，而且有助于识别研发线产品的风险状况。

基于应用的细分透过关注癌症治疗、心血管疾病、糖尿病管理和荷尔蒙失调等特定治疗领域，进一步细化了市场观点。这种方法确保我们为每个应用领域提供针对市场进入、法规遵循和病人参与製化策略。按居家医疗、医院诊所、实验室、专科诊所等最终用户进行细分，在使产品定位与客户需求和业务现实保持一致方面发挥着至关重要的作用。将这些不同的细分领域整合到整体分析中，将使相关人员能够更好地预测市场机会并解决临床创新与商业性可行性之间的复杂交互作用。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 越来越多的慢性疾病需要创新的口服蛋白质疗法
      • 随着营养意识的增强，口服蛋白质和胜肽补充剂的需求正在上升
    • 限制因素
      • 担心严重的副作用
    • 机会
      • 製药和生物技术合作推进口服蛋白质疗法
      • 大环肽开发的新焦点
    • 任务
      • 影响全球新型口服蛋白质疗法核准流程的监管障碍
  • 市场区隔分析
    • 产品类型：针对骨骼代谢紊乱和第 2 型糖尿病的胜肽疗法需求不断增长
    • 配方：胶囊配方由于易于给药且能够保护敏感的生物化合物而越来越受到青睐。
    • 开发阶段：探索口服蛋白质和胜肽的发展阶段多样性
    • 应用：癌症治疗中对口服蛋白质和胜肽的需求不断增加，以提高患者的依从性
    • 最终用户：居家照护环境中消费者对口服蛋白质和胜肽的偏好日益增长
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

6. 口服蛋白质和胜肽市场（依产品类型）

  • 介绍
  • 胰岛素类蛋白质
    • 结合胰岛素製剂
    • 长效胰岛素类似物
    • 速效胰岛素类似物
    • 重组人类胰岛素
  • 胜肽治疗方法
    • 以抑钙素为基础的治疗方法
    • Glucagon-Like Peptide-1受体促效剂
    • 加压素类似物

7. 口服蛋白质和胜肽市场（按配方）

  • 介绍
  • 胶囊剂型
  • 液体製剂
  • 粉末製剂
  • 锭剂配方

8. 口服蛋白质和胜肽市场（依发展阶段）

  • 介绍
  • I期和II期临床试验
  • III期临床试验
  • 上市后研究
  • 临床前研究

9. 口服蛋白质和胜肽市场（依应用）

  • 介绍
  • 癌症治疗
  • 心血管疾病
  • 糖尿病管理
  • 荷尔蒙失调

第 10 章。口服蛋白质和胜肽市场（按最终用户）

  • 介绍
  • 居家照护
  • 医院和诊所
  • 实验室
  • 专科诊所

11.美洲口服蛋白质和胜肽市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太地区口服蛋白质和胜肽市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲口服蛋白质和胜肽市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章竞争格局

  • 2023年市场占有率分析
  • 2023年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • AbbVie Inc.
  • Amgen Inc.
  • Amryt Pharma plc
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • Entera Bio Ltd. by DNA Biomedical Solutions
  • F. Hoffmann-La Roche AG
  • Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • PeptiDream Inc.
  • Pfizer, Inc.
  • Protagonist Therapeutics, Inc.
  • Proxima Concepts Limited
  • Rani Therapeutics, LLC
  • Sanofi SA
  • Tarsa Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Zealand Pharma A/S
Product Code: MRR-036C5CF3B4AA

The Oral Proteins & Peptides Market was valued at USD 6.10 billion in 2023 and is projected to grow to USD 6.89 billion in 2024, with a CAGR of 13.27%, reaching USD 14.60 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 6.10 billion
Estimated Year [2024] USD 6.89 billion
Forecast Year [2030] USD 14.60 billion
CAGR (%) 13.27%

Oral proteins and peptides have emerged as a focal point in the evolving landscape of therapeutics, offering transformative advantages in disease management and patient adherence. In recent years, significant advances in biotechnology and formulation science have paved the way for these molecules to transcend traditional administration barriers. There is an increasing emphasis on developing robust oral delivery systems that not only ensure bioavailability, but also enhance patient comfort and compliance. As research deepens and technology evolves, the market is witnessing a surge in interest from pharmaceutical developers, healthcare providers, and investors alike.

This comprehensive review details the current state of the market while also offering insights on future growth trajectories. It navigates through key trends, examines innovative formulation strategies, and evaluates the impact of regulatory frameworks on market expansion. The analysis is framed within an environment marked by rapid technological advancement and a global push for more effective, patient-centric therapies. This discussion is aimed at stakeholders who are known for their commitment to evidence-based decision-making and strategic market interventions. With evolving patient needs driving demand, the oral proteins and peptides market is set for disruptive breakthroughs that are poised to redefine treatment paradigms and optimize therapeutic outcomes.

From a strategic perspective, this document serves as an invaluable intellectual hub, offering data-backed insights and detailed qualitative analyses that help elucidate market behavior. The insights provided focus on integrating clinical advances and market strategies to address unmet medical needs. Ultimately, the synthesis of these insights sets the stage for a transformative journey, emphasizing the importance of aligning research, innovation, and commercialization activities in a tightly interconnected market.

Transformative Shifts in the Market Landscape and Their Strategic Implications

Over the past few years, the market for oral proteins and peptides has experienced transformative shifts, driven by rapid scientific breakthroughs and realignment of global healthcare priorities. Recent innovations in drug delivery systems have challenged the long-standing reliance on parenteral administration by introducing promising alternatives that effectively combine convenience with efficacy. This evolution is underpinned by a renewed focus on patient-centric approaches, advanced biotechnology, and strategic partnerships between research institutions and the pharmaceutical industry.

The advent of novel encapsulation techniques, improvements in peptide stability, and refinements in oral absorption enhancements are central to this transformation. Regulatory agencies are increasingly adapting their frameworks to accommodate breakthrough therapies, thereby accelerating approvals and fostering an environment that is receptive to innovation. In parallel with these technological advancements, market stakeholders have begun to reorient their strategies toward the development of integrated solutions that address both clinical requirements and economic sustainability. Decision-makers are now leveraging predictive analytics, big data, and risk-based monitoring to streamline research and development pipelines while minimizing time-to-market.

Additionally, the market has seen a significant realignment with respect to global investment flows, where emphasis is placed on targeting emerging therapeutic areas and underserved patient segments. As a result, traditional market players are compelled to rethink their operational frameworks and pursue dynamic, flexible business models. This shift is not merely an incremental improvement; it signifies a paradigm change that is redefining competitive strategies and forging new value propositions in clinical practice. In this environment, a forward-thinking approach, anchored in robust research and seamless execution, is essential to harnessing the benefits of these transformative changes.

Key Segmentation Insights Shaping Product Development and Market Strategy

A nuanced understanding of market segmentation underpins strategic planning and product development in the oral proteins and peptides space. The market is rigorously analyzed based on multiple dimensions, each yielding critical insights into its structure and growth potential. Firstly, product type segmentation distinguishes between Insulin-Based Proteins and Peptide Therapeutics. Further intricacies within this category reveal sub-segments such as Combination Insulin Products, Long-Acting Insulin Analogues, Rapid-Acting Insulin Analogues, and Recombinant Human Insulin, as well as segments corresponding to Calcitonin-Based Therapies, Glucagon-Like Peptide-1 Receptor Agonists, and Vasopressin Analogs. This detailed partitioning facilitates a deep dive into therapeutic efficacy, market penetration, and innovation trends.

The market is also segmented on the basis of formulation, where the importance of delivery format is underscored by the range of options available, such as Capsule Formulations, Liquid Formulations, Powder Formulations, and Tablet Formulations. These formats are continuously tested and optimized to improve patient compliance and clinical outcomes. In parallel, the development stage segmentation offers insights into the maturity level of therapeutics, categorized into Phase I & II Clinical Trials, Phase III Clinical Trials, Post-Market Surveillance, and Preclinical Studies. This segmentation not only highlights the research intensity but also aids in identifying the risk profile of pipeline products.

Application-based segmentation further refines the market perspective by focusing on specific therapeutic areas such as Cancer Treatment, Cardiovascular Diseases, Diabetes Management, and Hormonal Disorders. This approach ensures that each application area receives tailored strategies for market entry, regulatory compliance, and patient engagement. The segmentation based on end-user, which includes Home Care Settings, Hospitals & Clinics, Research Laboratories, and Specialty Clinics, plays a pivotal role in aligning product positioning to customer needs and operational realities. By integrating these various segmentation dimensions into a comprehensive analysis, stakeholders can better forecast market opportunities and address the complex interplay between clinical innovation and commercial viability.

Based on Product Type, market is studied across Insulin-Based Proteins and Peptide Therapeutics. The Insulin-Based Proteins is further studied across Combination Insulin Products, Long-Acting Insulin Analogues, Rapid-Acting Insulin Analogues, and Recombinant Human Insulin. The Peptide Therapeutics is further studied across Calcitonin-Based Therapies, Glucagon-Like Peptide-1 Receptor Agonists, and Vasopressin Analogs.

Based on Formulation, market is studied across Capsule Formulations, Liquid Formulations, Powder Formulations, and Tablet Formulations.

Based on Development Stage, market is studied across Phase I & II Clinical Trials, Phase III Clinical Trials, Post-Market Surveillance, and Preclinical Studies.

Based on Application, market is studied across Cancer Treatment, Cardiovascular Diseases, Diabetes Management, and Hormonal Disorders.

Based on End-User, market is studied across Home Care Settings, Hospitals & Clinics, Research Laboratories, and Specialty Clinics.

Key Regional Insights Illuminating Global Market Dynamics

The regional breakdown of the oral proteins and peptides market provides critical insight into localized trends and growth potentials. In the Americas, the market benefits from robust research ecosystems, substantial investment in biotechnology, and favorable regulatory environments. These factors create a fertile ground for rapid innovation and large-scale market adoption. Meanwhile, the combination of mature healthcare infrastructures and evolving patient needs in Europe, the Middle East, and Africa stimulates adoption of advanced therapeutic strategies. The region's diverse landscape supports both cutting-edge research and a gradual shift towards patient-focused therapy.

In the Asia-Pacific region, economic growth and expanding healthcare access are driving increased investments in pharmaceutical research and development. This dynamic span fosters an environment where emerging innovations in oral delivery systems are translated rapidly into clinical applications. The region is witnessing a growing enthusiasm towards integrating advanced therapeutic solutions into routine care, driven by rising healthcare awareness and proactive government policies. Each region, with its unique socio-economic and regulatory framework, influences the overall dynamics of the market. The interplay between regional strengths and market challenges provides a multi-faceted view of the global landscape, reinforcing the fact that geographical nuances are integral to strategic planning and market penetration efforts.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights Highlighting Industry Trailblazers and Innovators

The landscape of oral proteins and peptides is shaped by a network of industry-leading companies that are at the forefront of scientific and commercial innovation. Prominent players such as AbbVie Inc. and Amgen Inc. are renowned for their strong investment in research and a robust portfolio of advanced therapeutics. Companies like Amryt Pharma plc and Astellas Pharma Inc. leverage niche expertise to carve out significant market opportunities within specialized therapeutic areas.

Similarly, multinational corporations including AstraZeneca PLC and Boehringer Ingelheim International GmbH are redefining industry standards through strategic investments in R&D and partnerships that streamline the drug development process. Other innovators such as Catalent, Inc. and Entera Bio Ltd. by DNA Biomedical Solutions are noted for their state-of-the-art manufacturing capabilities and technological prowess that drive the efficient translation of research findings into market-ready products. Meanwhile, reputable names like F. Hoffmann-La Roche AG and Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital bring in a wealth of global experience and a strong commitment to patient-centric solutions. Johnson & Johnson Services, Inc., Merck KGaA, and Novartis AG contribute to the competitive landscape through expansive research networks and consolidated market presence, while Novo Nordisk A/S and Oramed Pharmaceuticals Inc. push forward the frontier in treatment innovation. Emerging companies such as PeptiDream Inc., Pfizer, Inc., Protagonist Therapeutics, Inc., Proxima Concepts Limited, Rani Therapeutics, LLC, Sanofi S.A., Tarsa Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., and Zealand Pharma A/S complete the mosaic of global leaders whose collective drive for excellence and innovation has ushered in new paradigms in the oral proteins and peptides market.

These companies not only invest heavily in research and development but are also adept at navigating complex regulatory environments and logistical challenges. Their strategic initiatives range from aggressive expansion into emerging markets to pioneering partnerships that leverage complementary expertise, thus ensuring a steady pipeline of innovative products designed for higher efficacy and improved patient outcomes.

The report delves into recent significant developments in the Oral Proteins & Peptides Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Amryt Pharma plc, Astellas Pharma Inc., AstraZeneca PLC, Biocon Limited, Boehringer Ingelheim International GmbH, Catalent, Inc., Entera Bio Ltd. by DNA Biomedical Solutions, F. Hoffmann-La Roche AG, Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital, Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., PeptiDream Inc., Pfizer, Inc., Protagonist Therapeutics, Inc., Proxima Concepts Limited, Rani Therapeutics, LLC, Sanofi S.A., Tarsa Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., and Zealand Pharma A/S. Actionable Recommendations for Industry Leaders to Capitalize on Market Opportunities

Industry leaders are encouraged to adopt a proactive and integrated approach to capturing market opportunities in the evolving oral proteins and peptides space. It is essential to intensify investments in advanced drug delivery systems as part of dedicated R&D initiatives, particularly focusing on enhancing bioavailability and patient compliance. Leaders should re-assess current portfolio strategies with a view toward diversification across multiple segmentation dimensions, such as product type, formulation, development stage, application, and end-user. This holistic strategy ensures that resources are optimally allocated towards both innovation and market expansion.

Embracing digital transformation tools can further streamline research and market analysis, enabling predictive modeling and more precise forecasting of clinical outcomes and market trends. Companies should consider collaborating with digital health startups and leveraging big data analytics to inform product development decisions and improve operational efficiencies. Additionally, pursuing strategic alliances and partnerships, whether through mergers, acquisitions, or research collaborations, could significantly mitigate risk while enhancing the flow of technological innovation. This approach not only broadens the scope for breakthrough research but also shortens the time to market for novel therapeutics.

In parallel, market leaders must remain agile in navigating evolving regulatory landscapes. A continuous dialogue with regulatory bodies, coupled with proactive compliance and robust quality control systems, will be critical to overcoming barriers and expediting market entry. In this highly competitive environment, it is also advisable to invest in building a flexible yet resilient supply chain to support rapid scaling and distribution of new products. Ultimately, adopting an integrated strategy that emphasizes innovation, collaboration, and operational excellence will enhance a company's ability to capitalize on the emerging opportunities in the oral proteins and peptides market.

Conclusion: Harnessing Innovation and Strategic Alliances to Drive Future Growth

In summary, the oral proteins and peptides market is undergoing a period of significant transformation. In light of rapid technological progress, shifting consumer expectations, and dynamic regulatory environments, the market presents promising growth trajectories and an array of opportunities for stakeholders worldwide. Detailed analysis indicates that diversified segmentation - spanning from product types and formulations to clinical trial phases and application domains - provides a comprehensive framework for understanding market intricacies. Regional nuances further corroborate that tailored strategies are essential to address localized challenges and leverage unique market strengths.

The insights outlined in this summary reflect a blend of cutting-edge research and real-world strategic initiatives. They underscore the importance of innovation, improved clinical practices, and adaptive operational models in overcoming market uncertainties. As technological advancements continue to push the boundaries of what is clinically possible, the integration of these insights into business strategy is key to achieving sustained growth and competitive advantage. The journey forward will depend on the ability of industry leaders to forge strategic alliances, embrace new technologies, and continuously adapt to an evolving market landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic diseases demanding innovative oral protein therapeutics
      • 5.1.1.2. Growing need for oral protein and peptide supplements with growing nutritional awareness
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with significant side effects
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborative partnerships between pharma and biotech companies for advancing oral protein therapies
      • 5.1.3.2. Emerging focus on the development of macrocyclic peptides
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory hurdles affecting the approval processes for new oral protein-based therapeutics globally
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Increasing need for peptide therapeutics targeting bone metabolism disorders and Type 2 diabetes
    • 5.2.2. Formulation: Growing preferences for capsule formulations owing to their ease of administration and ability to protect sensitive biological compounds
    • 5.2.3. Development Stage: Exploring diversities across developmental stages in oral proteins & peptides
    • 5.2.4. Application: Growing demand for oral proteins and peptides in cancer treatment for enhancing patient compliance
    • 5.2.5. End-User: Rising consumer preference for oral proteins and peptides in home care settings
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Oral Proteins & Peptides Market, by Product Type

  • 6.1. Introduction
  • 6.2. Insulin-Based Proteins
    • 6.2.1. Combination Insulin Products
    • 6.2.2. Long-Acting Insulin Analogues
    • 6.2.3. Rapid-Acting Insulin Analogues
    • 6.2.4. Recombinant Human Insulin
  • 6.3. Peptide Therapeutics
    • 6.3.1. Calcitonin-Based Therapies
    • 6.3.2. Glucagon-Like Peptide-1 Receptor Agonists
    • 6.3.3. Vasopressin Analogs

7. Oral Proteins & Peptides Market, by Formulation

  • 7.1. Introduction
  • 7.2. Capsule Formulations
  • 7.3. Liquid Formulations
  • 7.4. Powder Formulations
  • 7.5. Tablet Formulations

8. Oral Proteins & Peptides Market, by Development Stage

  • 8.1. Introduction
  • 8.2. Phase I & II Clinical Trials
  • 8.3. Phase III Clinical Trials
  • 8.4. Post-Market Surveillance
  • 8.5. Preclinical Studies

9. Oral Proteins & Peptides Market, by Application

  • 9.1. Introduction
  • 9.2. Cancer Treatment
  • 9.3. Cardiovascular Diseases
  • 9.4. Diabetes Management
  • 9.5. Hormonal Disorders

10. Oral Proteins & Peptides Market, by End-User

  • 10.1. Introduction
  • 10.2. Home Care Settings
  • 10.3. Hospitals & Clinics
  • 10.4. Research Laboratories
  • 10.5. Specialty Clinics

11. Americas Oral Proteins & Peptides Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Oral Proteins & Peptides Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Oral Proteins & Peptides Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. CordenPharma's EUR 900 million investment aims to transform peptide manufacturing across the US and Europe
    • 14.3.2. Glanbia Nutritionals revolutionizes collagen supplementation with the launch of fast-absorbing Collameta
    • 14.3.3. Incyte expands inflammation portfolio with Escient acquisition, introducing novel oral MRGPR antagonists
    • 14.3.4. Johnson & Johnson achieves promising phase II results with JNJ-2113, a groundbreaking oral peptide for plaque psoriasis
    • 14.3.5. Orbis Medicines revolutionizes oral peptide drug delivery with EUR 26 million funding to enhance patient experience
    • 14.3.6. Novartis acquisition of MorphoSys AG strengthens oncology pipeline with focus on oral proteins and peptides
    • 14.3.7. Innovative partnership between Vivtex and AI Proteins aims to revolutionize oral therapies for inflammation
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. AstraZeneca PLC
    • 14.4.2. Johnson & Johnson Services, Inc.
    • 14.4.3. Novo Nordisk A/S
    • 14.4.4. Novartis AG

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Amryt Pharma plc
  • 4. Astellas Pharma Inc.
  • 5. AstraZeneca PLC
  • 6. Biocon Limited
  • 7. Boehringer Ingelheim International GmbH
  • 8. Catalent, Inc.
  • 9. Entera Bio Ltd. by DNA Biomedical Solutions
  • 10. F. Hoffmann-La Roche AG
  • 11. Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital
  • 12. Johnson & Johnson Services, Inc.
  • 13. Merck KGaA
  • 14. Novartis AG
  • 15. Novo Nordisk A/S
  • 16. Oramed Pharmaceuticals Inc.
  • 17. PeptiDream Inc.
  • 18. Pfizer, Inc.
  • 19. Protagonist Therapeutics, Inc.
  • 20. Proxima Concepts Limited
  • 21. Rani Therapeutics, LLC
  • 22. Sanofi S.A.
  • 23. Tarsa Therapeutics, Inc.
  • 24. Teva Pharmaceutical Industries Ltd.
  • 25. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. ORAL PROTEINS & PEPTIDES MARKET MULTI-CURRENCY
  • FIGURE 2. ORAL PROTEINS & PEPTIDES MARKET MULTI-LANGUAGE
  • FIGURE 3. ORAL PROTEINS & PEPTIDES MARKET RESEARCH PROCESS
  • FIGURE 4. ORAL PROTEINS & PEPTIDES MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ORAL PROTEINS & PEPTIDES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. ORAL PROTEINS & PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ORAL PROTEINS & PEPTIDES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ORAL PROTEINS & PEPTIDES MARKET DYNAMICS
  • TABLE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COMBINATION INSULIN PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LONG-ACTING INSULIN ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RAPID-ACTING INSULIN ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RECOMBINANT HUMAN INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN-BASED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY VASOPRESSIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CAPSULE FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POWDER FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY TABLET FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE I & II CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRECLINICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 103. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 110. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 117. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 124. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 131. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 138. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 145. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 152. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 159. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 166. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 173. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 188. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 195. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 202. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 209. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 216. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 223. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 230. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 231. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 237. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 244. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 251. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 252. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 258. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 259. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 265. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 272. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 278. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 279. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 280. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 286. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 287. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 292. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 293. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 294. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 299. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 300. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 306. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 307. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 308. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 313. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 314. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 315. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE,